英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

verisimilar    
a. 好象真实的

好象真实的

verisimilar
adj 1: appearing to be true or real; "a verisimilar tale"

Verisimilar \Ver`i*sim"i*lar\, a. [L. verisimilis; verus true
similis like, similar. See {Very}, and {Similar}.]
Having the appearance of truth; probable; likely. "How
verisimilar it looks." --Carlyle.
[1913 Webster]

78 Moby Thesaurus words for "verisimilar":
apt, authentic, bona fide, candid, card-carrying, dinkum, fair,
following the letter, foreseeable, genuine, good, honest,
honest-to-God, hopeful, in the cards, inartificial, lawful,
legitimate, liable, lifelike, likely, literal, natural,
naturalistic, odds-on, original, predictable,
predictable within limits, presumable, presumptive, probable,
promising, pure, real, realistic, rightful, simon-pure, simple,
sincere, statistically probable, sterling, sure-enough,
true to life, true to nature, true to reality, unadulterated,
unaffected, unassumed, unassuming, uncolored, unconcocted,
uncopied, uncounterfeited, undisguised, undisguising, undistorted,
unexaggerated, unfabricated, unfanciful, unfeigned, unfeigning,
unfictitious, unflattering, unimagined, unimitated, uninvented,
unpretended, unpretending, unqualified, unromantic, unsimulated,
unspecious, unsynthetic, unvarnished, verbal, verbatim, veridical,
word-for-word


请选择你想看的字典辞典：
单词字典翻译
verisimilar查看　verisimilar　在百度字典中的解释百度英翻中〔查看〕
verisimilar查看　verisimilar　在Google字典中的解释Google英翻中〔查看〕
verisimilar查看　verisimilar　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • FDA approves cemiplimab-rwlc for adjuvant treatment of . . .
    On October 8, 2025, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals Inc ) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma
  • FDA Approves Libtayo for Immunotherapy for Adjuvant Treatment . . .
    FDA approved of Regeneron Pharmaceutical’s Libtayo (cemiplimab-rwlc)as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (CSCC) who are at an increased risk of recurrence following surgery and radiation 1 Libtayo was reviewed by FDA under Priority Review, a method reserved for medicines representing a potential improvement in efficacy or safety in treatments of
  • Libtayo (cemiplimab-rwlc) FDA Approval History - Drugs. com
    Libtayo (cemiplimab-rwlc) is a programmed death receptor-1 (PD-1) blocking antibody for the treatment of cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma (BCC), and non-small cell lung cancer (NSCLC)
  • FDA Approves Cemiplimab for Adjuvant Cutaneous Squamous Cell . . .
    The US FDA has approved the supplemental biologics license application (sBLA) for cemiplimab-rwlc (Libtayo) as adjuvant treatment in adults with high-risk cutaneous squamous cell carcinoma (CSCC) 1 The sBLA approval was based on an extensive review of data from the pivotal phase 3 C-POST study (NCT03969004) which demonstrated a statistically significant and clinically meaningful improvement
  • FDA Approves Cemiplimab as Adjuvant Immunotherapy for High . . .
    Last week, Regeneron announced the U S Food and Drug Administration (FDA) approval of cemiplimab-rwlc (Libtayo) as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (CSCC), particularly in those with a high risk of recurrence after surgery and radiation 1 The PD-1 inhibitor was evaluated under priority review
  • FDA approves Regenerons Libtayo for high-risk CSCC
    The US Food and Drug Administration (FDA) has granted approval to Regeneron Pharmaceuticals’ fully human monoclonal antibody Libtayo (cemiplimab-rwlc) as an adjuvant therapy for adults with cutaneous squamous cell carcinoma (CSCC) The approval is intended for patients who face an increased risk of the disease returning after surgery and radiation
  • FDA Approves Libtayo for Adjuvant Treatment of High-Risk CSCC
    The FDA has approved Libtayo for the adjuvant treatment of adult patients with CSCC at high risk of recurrence after surgery and radiation
  • Libtayo® (cemiplimab-rwlc) Approved in the U. S. as First and . . .
    The FDA evaluated Libtayo under Priority Review, which is reserved for medicines that represent potentially significant improvements in efficacy or safety in the treatment of serious conditions
  • FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy . . .
    Cemiplimab is the first immunotherapy approved for adjuvant treatment in CSCC, offering a new option for patients at high risk of recurrence
  • Covering Every FDA Oncology Approval From October 2025
    FDA Approves Libtayo for High-Risk Cutaneous Squamous Cell Carcinoma The FDA has approved Libtayo (cemiplimab-rwlc) for adjuvant treatment in adults with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation This approval was based on the C-POST trial, which included 415 patients at high risk of recurrence





中文字典-英文字典  2005-2009